NeoPharm CO. LTD (092730) — Capital Reinvestment Ratio
NeoPharm CO. LTD (092730) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩5.88 Billion) in capital expenditures (₩446.60 Million). See 092730 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
NeoPharm CO. LTD Capital Reinvestment Ratio (2012–2024)
This chart tracks NeoPharm CO. LTD's Capital Reinvestment Ratio across 11 annual periods. Check 092730 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for NeoPharm CO. LTD (2012–2024)
Year-by-year Capital Reinvestment Ratio for NeoPharm CO. LTD from 2012 to 2024. For live market cap and broader valuation context, see 092730 market cap.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.17x | ₩18.63 Billion | ₩3.08 Billion | ▼ -81.6% |
| 2023 | 0.90x | ₩23.26 Billion | ₩20.83 Billion | ▲ +1916.3% |
| 2022 | 0.04x | ₩18.16 Billion | ₩806.43 Million | ▲ +200.8% |
| 2021 | 0.01x | ₩21.68 Billion | ₩320.11 Million | ▼ -11.7% |
| 2020 | 0.02x | ₩17.07 Billion | ₩285.62 Million | ▼ -94.6% |
| 2019 | 0.31x | ₩19.22 Billion | ₩5.90 Billion | ▲ +155.9% |
| 2018 | 0.12x | ₩16.18 Billion | ₩1.94 Billion | ▲ +44.4% |
| 2017 | 0.08x | ₩10.65 Billion | ₩884.71 Million | ▼ -45.8% |
| 2016 | 0.15x | ₩9.16 Billion | ₩1.40 Billion | ▲ +18.8% |
| 2015 | 0.13x | ₩6.09 Billion | ₩786.89 Million | ▼ -57.8% |
| 2012 | 0.31x | ₩564.34 Million | ₩172.47 Million | — |